Comparable Safety and No Emergent Resistance With Ceftobiprole vs Daptomycin in S aureus Bacteremia

In a discussion of the ERADICATE trial, clinicians highlighted that the overall safety profiles of ceftobiprole and daptomycin were broadly similar, with no meaningful differences in serious adverse events or treatment discontinuations. Gastrointestinal side effects—such as mild nausea—were observed more frequently with ceftobiprole, but these events were generally mild and rarely led to stopping therapy, placing them in line with what is typically seen across the broader beta-lactam class.

From a clinical perspective, these differences are not considered highly significant, as they are unlikely to alter treatment decisions for most patients given the low severity and low discontinuation rates. Instead, they mainly serve as a tolerability consideration in individual cases rather than a differentiating safety concern.

A more notable finding from the trial was the absence of treatment-emergent resistance in the ceftobiprole group, contrasted with a small number of resistance cases observed in the daptomycin arm. This distinction is clinically relevant in the broader context of antimicrobial resistance (AMR), as it suggests ceftobiprole may have a more stable resistance profile in the setting of Staphylococcus aureus bacteremia. By contrast, the emergence of daptomycin resistance, while not unexpected given historical data, reinforces its known limitation in certain treatment failures.

Overall, the results support ceftobiprole as a potentially durable alternative with a reassuring safety profile and a favorable resistance signal, while daptomycin remains an effective comparator with well-characterized but occasionally limiting resistance risk.

Disclaimer: Holland was the Chair of Adjudication for the ERADICATE trial.

This video series has been produced independently by Contagion Live and supported through a educational grant by Innoviva Specialty Therapeutics inc